Literature DB >> 28700550

CAR-Ts move beyond B-cell cancers to myeloma.

Elie Dolgin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28700550     DOI： 10.1038/nbt0717-599

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis.

Authors:  Michael Rosenzweig; Ryan Urak; Miriam Walter; Laura Lim; James F Sanchez; Amrita Krishnan; Stephen Forman; Xiuli Wang
Journal:  Cytotherapy       Date:  2017-05-05       Impact factor: 5.414

2.  Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.

Authors:  Alfred L Garfall; Marcela V Maus; Wei-Ting Hwang; Simon F Lacey; Yolanda D Mahnke; J Joseph Melenhorst; Zhaohui Zheng; Dan T Vogl; Adam D Cohen; Brendan M Weiss; Karen Dengel; Naseem D S Kerr; Adam Bagg; Bruce L Levine; Carl H June; Edward A Stadtmauer
Journal:  N Engl J Med       Date:  2015-09-10       Impact factor: 91.245
  2 in total
  3 in total

1.  BCMA CAR T-cell therapy arrives for multiple myeloma: a reality.

Authors:  Shih-Feng Cho; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Ann Transl Med       Date:  2018-12

Review 2.  Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing.

Authors:  Zihai Li; Wenru Song; Mark Rubinstein; Delong Liu
Journal:  J Hematol Oncol       Date:  2018-12-21       Impact factor: 17.388

Review 3.  Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.

Authors:  Shih-Feng Cho; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Front Immunol       Date:  2018-08-10       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.